ロード中...
Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database
PURPOSE: Infliximab, which was approved in 2002, had its first biosimilar launched in 2014 across Japan. However, the penetration rate of this biosimilar remains unclear given the limited data regarding its current clinical use throughout Japan. This study was conducted to describe the current clini...
保存先:
| 出版年: | Clinicoecon Outcomes Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7920501/ https://ncbi.nlm.nih.gov/pubmed/33658813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S293698 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|